05/2021: Tcell Tolerance GmbH assigned UGA Biopharma to develop a highly efficient CHO cell line and bioprocess

UGA Biopharma is developing a new and more efficient CHO-DG44 cell line for German-based startup Tcell Tolerance GmbH to express its Palixizumab® antibody.

The new cell line will assist Tcell Tolerance in its quest to develop an innovative therapy to prevent graft-versus-host disease (GvHD), which occurs after allogeneic hematopoietic stem-cell transplantation (HSCT). Tcell Tolerance wants to develop a safer HSCT therapy that can be translated into clinical practice.

To read the full article, please click here.


UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900